<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05043610</url>
  </required_header>
  <id_info>
    <org_study_id>IR.SUMS.REC.1400.409</org_study_id>
    <nct_id>NCT05043610</nct_id>
  </id_info>
  <brief_title>MSCs for Prevention of MI-induced HF</brief_title>
  <acronym>PREVENT-TAHA</acronym>
  <official_title>Transplantation of Mesenchymal Stem Cells for Prevention of Acute Myocardial Infarction Induced Heart Failure: A Phase III Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Medical Research Development (NIMAD), Iran</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cell Tech Pharmed Company, Iran</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Results from recent clinical trials on bone marrow mononuclear cell (BM-MNC) transplantation&#xD;
      show that this intervention can help reduce the incidence of heart failure (HF) after acute&#xD;
      myocardial infarction (AMI). However, no study has evaluated the effect of the&#xD;
      transplantation of mesenchymal stem cells (MSCs) on a clinical endpoint such as HF.&#xD;
&#xD;
      This single-blinded, randomized, multicenter trial aims to establish whether the&#xD;
      intracoronary infusion of umbilical cord-derived Wharton's jelly MSCs (WJ-MSCs) helps prevent&#xD;
      HF development after AMI. The study will enroll 240 patients 3 to 7 days following an AMI&#xD;
      treated with primary percutaenous coronary intervention (PPCI). Only patients aged below 65&#xD;
      years with impaired LV function (LVEF &lt; 40%) will be included. They will be randomized to&#xD;
      receive either a single intracoronary infusion of WJ-MSCs or standard care. The primary&#xD;
      outcome of this study is the assessment of HF development during long-term follow-up (four&#xD;
      years). Since the efficacy of MSCs is higher than BM-MNCs after AMI in the improvement of&#xD;
      LVEF, it would be probable that these cells may have a better clinical effect as well.&#xD;
      However, no study has evaluated the impact of the transplantation of MSCs on a clinical&#xD;
      endpoint such as HF. This study will help determine whether or not the infusion of&#xD;
      intracoronary WJ-MSCs in patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, multicenter, single-blinded phase III trial will be conducted to assess whether&#xD;
      the intracoronary infusion of umbilical cord WJ-MSCs demonstrates a superior effect in&#xD;
      reducing HF incidence following AMIs compared to standard treatment.&#xD;
&#xD;
      The sample size was determined with a 5% error, 80% power, a one-year HF incidence rate of&#xD;
      1.3-4%, and division between two groups in a 2:1 ratio (control:intervention), and a&#xD;
      three-year follow-up period.&#xD;
&#xD;
      A total of 360 patients with a history of an anterior ST-elevation MI (STEMI) successfully&#xD;
      reperfused within standard golden time within 3-7 days after AMI will be enrolled.&#xD;
&#xD;
      Randomization will be done via permuted block randomization through a web-based service. A&#xD;
      block size of 4 will be considered. Two groups of equal proportion will be formed, where only&#xD;
      one will receive an intracoronary infusion of WJ-MSCs besides the conventional therapy&#xD;
      provided to both groups. Those who assess the study outcomes will remain unaware of the&#xD;
      allocation (single-blind).&#xD;
&#xD;
      This study will use cGMP-certified clinical-grade human WJ-MSCs (Cell Tech Pharmed Co. Ltd.,&#xD;
      Tehran, Iran).In the intervention group, all 120 patients will receive a single intracoronary&#xD;
      infusion of 107 WJ-MSCs alongside the conventional treatment that will be provided to the&#xD;
      same number of patients in the control group. Patients in the intervention group will be&#xD;
      taken to the cardiac catheterization lab, where the infusion of 107 WJ-MSCs will be done&#xD;
      through the intracoronary route.&#xD;
&#xD;
      Before statistical analysis, adjudication of all measurements will be done by an experienced&#xD;
      cardiology department member excluded from the research group. The adjudicator will assess&#xD;
      the quality of each measurement and will exclude those with inadequate quality from the&#xD;
      analysis, where they will be regarded as missing. An independent, blinded safety committee&#xD;
      will evaluate potential major adverse cardiac events (MACEs). Once the adjudication process&#xD;
      is complete, the finalized database will be unblinded.&#xD;
&#xD;
      Data will be kept anonymous until analysis, which is to be performed by an independent&#xD;
      statistician external to the research group. Treatment efficacy will be assessed according to&#xD;
      the decrement in HF with the help of Cox regression analysis. The investigators will consider&#xD;
      the EF to have improved significantly if a minimum increment of 3% is achieved after six&#xD;
      months. The analysis will follow the intention-to-treat approach. The baseline&#xD;
      characteristics of the two study groups will also be compared. Continuous variables will be&#xD;
      summarized using the mean and standard deviation, while frequencies and percentages will be&#xD;
      given for categorical data. The EF, as the primary outcome, will be compared between the&#xD;
      study groups using the independent t-test and one-way analysis of variance (ANOVA). The&#xD;
      therapeutic effect will be estimated with a 95% CI. Two-sided P-values will be used. Safety&#xD;
      will be compared between the two groups according to the occurrence of MACEs (death,&#xD;
      recurrent AMI, ICD insertion, non-target vessel revascularization, etc.) and serious adverse&#xD;
      events (SAEs). These events will be followed over time with Kaplan-Meier curves, which will&#xD;
      allow us to understand their patterns. With the help of the Cox proportional hazards model,&#xD;
      The investigators will assess the statistical significance and 95% CI.&#xD;
&#xD;
      Data will be kept anonymous until analysis, which is to be performed by an independent&#xD;
      statistician external to the research group. Treatment efficacy will be assessed according to&#xD;
      the decrement in HF with the help of Cox regression analysis. The investigators will consider&#xD;
      the EF to have improved significantly if a minimum increment of 3% is achieved after six&#xD;
      months. The analysis will follow the intention-to-treat approach. The baseline&#xD;
      characteristics of the two study groups will also be compared. Continuous variables will be&#xD;
      summarized using the mean and standard deviation, while frequencies and percentages will be&#xD;
      given for categorical data. The EF, as the primary outcome, will be compared between the&#xD;
      study groups using the independent t-test and one-way analysis of variance (ANOVA). The&#xD;
      therapeutic effect will be estimated with a 95% CI. Two-sided P-values will be used. Safety&#xD;
      will be compared between the two groups according to the occurrence of MACEs (death,&#xD;
      recurrent AMI, ICD insertion, non-target vessel revascularization, etc.) and serious adverse&#xD;
      events (SAEs). These events will be followed over time with Kaplan-Meier curves, which will&#xD;
      allow us to understand their patterns. With the help of the Cox proportional hazards model,&#xD;
      The investigators will assess the statistical significance and 95% CI.&#xD;
&#xD;
      Adverse events will be reported by the study's executive committee to an independent Data and&#xD;
      Safety and Monitoring Board (DSMB). The DSMB will have the authority to stop the trial early&#xD;
      if patient safety is compromised or if the primary research objective is met. All safety&#xD;
      issues (unanticipated SAEs, mortality, intracoronary infusion complications, and severe&#xD;
      arrhythmias, etc.) will be monitored by the DSMB, and the DSMB statistician will report the&#xD;
      occurrence of safety issues in each study group quarterly. All deaths will be reported.&#xD;
&#xD;
      The investigators have discussed all ethical issues with the Institutional Review Board of&#xD;
      Shiraz University of Medical Sciences, which ultimately approved the study protocol&#xD;
      (IR.SUMS.REC.1400.409). Informed consent will be obtained once patients are clinically stable&#xD;
      and sedatives or strong analgesics do not alter their consciousness. Importantly, the use of&#xD;
      low balloon inflation pressure and divided (three-part) infusions will prevent complications&#xD;
      related to intracoronary cell infusion. The principles of the Declaration of Helsinki will be&#xD;
      upheld throughout this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A single-blinded, randomized, multicenter trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Single-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Heart Failure</measure>
    <time_frame>Checked at three years</time_frame>
    <description>The incidence of heart failure during the follow-up period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Function from base line</measure>
    <time_frame>At baseline and after six months</time_frame>
    <description>Measurement of left ventricular function with echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Death</measure>
    <time_frame>Checked at three years</time_frame>
    <description>Occurrence of mortality due to cardiovascular causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite outcome of cardiovascular death and heart failure incidence</measure>
    <time_frame>Checked at three years</time_frame>
    <description>Occurrence of mortality due to cardiovascular causes or heart failure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Myocardial Infarction, Acute</condition>
  <condition>Myocardial Infarction First</condition>
  <condition>Myocardial Infarction, Anterior Wall</condition>
  <condition>Cardiac Remodeling, Ventricular</condition>
  <condition>STEMI</condition>
  <condition>Regenerative Medicine</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the experimental group, 3-7 days after an acute anterior myocardial infarction treated successfully with primary percutaneous coronary intervention, 120 patients will receive a single intracoronary infusion of 10^7 umbilical cord-derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs) alongside conventional treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (Control Group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the control group, after an acute anterior myocardial infarction treated successfully with primary percutaneous coronary intervention, 120 patients will receive only conventional treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs)</intervention_name>
    <description>Cell Tech Pharmed Company (Tehran, Iran) will provide us with cGMP grade WJ-MSCs. 10^7 WJ-MSCs will be delivered through the intracoronary route. WJ-MSCs will be infused at a rate of 2.5 ml/min across three portions.</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional Treatment</intervention_name>
    <description>Beta-blocker, angiotensin-converting enzyme (ACE) inhibitor, aldosterone antagonist, aspirin, ticagrelor, statin, and glyceryl trinitrate plus cardiac rehabilitation.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2 (Control Group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-65 years&#xD;
&#xD;
          -  Either gender&#xD;
&#xD;
          -  First myocardial infarction in the preceding 3 to 7 days&#xD;
&#xD;
          -  Post-acute myocardial infarction left ventricular ejection fraction &lt; 40%&#xD;
&#xD;
          -  Negative pregnancy test (for women of reproductive age)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of any prior cardiac conditions (valvular, ischemic, or congenital&#xD;
             disorders)&#xD;
&#xD;
          -  Regional wall motion abnormalities outside the region of the infarction&#xD;
&#xD;
          -  LV dysfunction due to other etiologies like non-ischemic cardiomyopathy, anthracycline&#xD;
             use, or ethanol abuse (&gt; 6 oz./day regularly)&#xD;
&#xD;
          -  Poor echocardiography window&#xD;
&#xD;
          -  Active infection, malignancy, or autoimmune disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armin Attar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Cardiovascular Medicine, TAHA clinical trial group, Shiraz University of Medical Sciences, Shiraz, Iran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Armin Attar, MD</last_name>
    <phone>9177141797</phone>
    <phone_ext>+98</phone_ext>
    <email>attarar@sums.ac.ir</email>
  </overall_contact>
  <location>
    <facility>
      <name>Al-Zahra Heart Hospital, Shiraz University of Medical Sciences</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armin Attar, MD</last_name>
      <phone>+989177141797</phone>
      <email>attarar@sums.ac.ir</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faghihi Hospital</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javad Kojouri, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Namazee Hospital</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peyman Izadpanah, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Velagaleti RS, Pencina MJ, Murabito JM, Wang TJ, Parikh NI, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation. 2008 Nov 11;118(20):2057-62. doi: 10.1161/CIRCULATIONAHA.108.784215. Epub 2008 Oct 27.</citation>
    <PMID>18955667</PMID>
  </reference>
  <reference>
    <citation>Hellermann JP, Jacobsen SJ, Gersh BJ, Rodeheffer RJ, Reeder GS, Roger VL. Heart failure after myocardial infarction: a review. Am J Med. 2002 Sep;113(4):324-30.</citation>
    <PMID>12361819</PMID>
  </reference>
  <reference>
    <citation>Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation. 2012 Jan 3;125(1):e2-e220. doi: 10.1161/CIR.0b013e31823ac046. Epub 2011 Dec 15. Erratum in: Circulation. 2012 Jun 5;125(22):e1002.</citation>
    <PMID>22179539</PMID>
  </reference>
  <reference>
    <citation>WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016 Sep 27;134(13):e282-93. doi: 10.1161/CIR.0000000000000435. Epub 2016 May 20. Erratum in: Circulation. 2016 Sep 27;134(13):e298.</citation>
    <PMID>27208050</PMID>
  </reference>
  <reference>
    <citation>Juillière Y, Cambou JP, Bataille V, Mulak G, Galinier M, Gibelin P, Benamer H, Bouvaist H, Méneveau N, Tabone X, Simon T, Danchin N; FAST-MI Investigators. Heart failure in acute myocardial infarction: a comparison between patients with or without heart failure criteria from the FAST-MI registry. Rev Esp Cardiol (Engl Ed). 2012 Apr;65(4):326-33. doi: 10.1016/j.recesp.2011.10.027. Epub 2012 Feb 20.</citation>
    <PMID>22357361</PMID>
  </reference>
  <reference>
    <citation>Lewis EF, Moye LA, Rouleau JL, Sacks FM, Arnold JM, Warnica JW, Flaker GC, Braunwald E, Pfeffer MA; CARE Study. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol. 2003 Oct 15;42(8):1446-53.</citation>
    <PMID>14563590</PMID>
  </reference>
  <reference>
    <citation>Braunwald E. Cell-Based Therapy in Cardiac Regeneration: An Overview. Circ Res. 2018 Jul 6;123(2):132-137. doi: 10.1161/CIRCRESAHA.118.313484. Review.</citation>
    <PMID>29976683</PMID>
  </reference>
  <reference>
    <citation>Taylor DA, Atkins BZ, Hungspreugs P, Jones TR, Reedy MC, Hutcheson KA, Glower DD, Kraus WE. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med. 1998 Aug;4(8):929-33. Erratum in: Nat Med 1998 Oct;4(10):1200.</citation>
    <PMID>9701245</PMID>
  </reference>
  <reference>
    <citation>Leor J, Patterson M, Quinones MJ, Kedes LH, Kloner RA. Transplantation of fetal myocardial tissue into the infarcted myocardium of rat. A potential method for repair of infarcted myocardium? Circulation. 1996 Nov 1;94(9 Suppl):II332-6.</citation>
    <PMID>8901770</PMID>
  </reference>
  <reference>
    <citation>Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature. 2001 Apr 5;410(6829):701-5.</citation>
    <PMID>11287958</PMID>
  </reference>
  <reference>
    <citation>Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NM, Itescu S. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001 Apr;7(4):430-6.</citation>
    <PMID>11283669</PMID>
  </reference>
  <reference>
    <citation>Menasché P, Hagège AA, Scorsin M, Pouzet B, Desnos M, Duboc D, Schwartz K, Vilquin JT, Marolleau JP. Myoblast transplantation for heart failure. Lancet. 2001 Jan 27;357(9252):279-80.</citation>
    <PMID>11214133</PMID>
  </reference>
  <reference>
    <citation>Assmus B, Schächinger V, Teupe C, Britten M, Lehmann R, Döbert N, Grünwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S, Zeiher AM. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002 Dec 10;106(24):3009-17.</citation>
    <PMID>12473544</PMID>
  </reference>
  <reference>
    <citation>Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011 Sep 30;109(8):923-40. doi: 10.1161/CIRCRESAHA.111.243147. Review.</citation>
    <PMID>21960725</PMID>
  </reference>
  <reference>
    <citation>Houtgraaf JH, den Dekker WK, van Dalen BM, Springeling T, de Jong R, van Geuns RJ, Geleijnse ML, Fernandez-Aviles F, Zijlsta F, Serruys PW, Duckers HJ. First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2012 Jan 31;59(5):539-40. doi: 10.1016/j.jacc.2011.09.065.</citation>
    <PMID>22281257</PMID>
  </reference>
  <reference>
    <citation>Karantalis V, Schulman IH, Balkan W, Hare JM. Allogeneic cell therapy: a new paradigm in therapeutics. Circ Res. 2015 Jan 2;116(1):12-5. doi: 10.1161/CIRCRESAHA.114.305495.</citation>
    <PMID>25552688</PMID>
  </reference>
  <reference>
    <citation>Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Byrnes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW, George R, Lardo A. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012 Dec 12;308(22):2369-79. Erratum in: JAMA. 2013 Aug 21;310(7):750. George, Richard [added]; Lardo, Albert [added].</citation>
    <PMID>23117550</PMID>
  </reference>
  <reference>
    <citation>Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res. 2013 Aug 30;113(6):810-34. doi: 10.1161/CIRCRESAHA.113.300219. Review.</citation>
    <PMID>23989721</PMID>
  </reference>
  <reference>
    <citation>Jeong H, Yim HW, Park HJ, Cho Y, Hong H, Kim NJ, Oh IH. Mesenchymal Stem Cell Therapy for Ischemic Heart Disease: Systematic Review and Meta-analysis. Int J Stem Cells. 2018 May 30;11(1):1-12. doi: 10.15283/ijsc17061. Review.</citation>
    <PMID>29482311</PMID>
  </reference>
  <reference>
    <citation>Gao LR, Chen Y, Zhang NK, Yang XL, Liu HL, Wang ZG, Yan XY, Wang Y, Zhu ZM, Li TC, Wang LH, Chen HY, Chen YD, Huang CL, Qu P, Yao C, Wang B, Chen GH, Wang ZM, Xu ZY, Bai J, Lu D, Shen YH, Guo F, Liu MY, Yang Y, Ding YC, Yang Y, Tian HT, Ding QA, Li LN, Yang XC, Hu X. Intracoronary infusion of Wharton's jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial. BMC Med. 2015 Jul 10;13:162. doi: 10.1186/s12916-015-0399-z.</citation>
    <PMID>26162993</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 29, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Armin Attar</investigator_full_name>
    <investigator_title>Director of cardiovascular regeneration and genetics program, and cardiovascular diseases' registries, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>WJ-MSCs</keyword>
  <keyword>Myocardial infarction</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Regenerative medicine</keyword>
  <keyword>Tissue therapy</keyword>
  <keyword>Stem cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Anterior Wall Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We plan to publish the study protocol soon. The final results will be published in the form of an article after the study is completed.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>The study protocol will be submitted for publishing within six months.</ipd_time_frame>
    <ipd_access_criteria>Supporting data will be made available upon reasonable request. All inquiries should be sent to the study director, Dr. Armin Attar.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

